NASDAQ · ANNX
Annexon, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ANNX: Nov 9, 2026
Annexon, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.28. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.28 | $-0.27 | $-0.29 | 4 |
| Dec 2026 | $-0.27 | $-0.24 | $-0.30 | 3 |
| Mar 2027 | $-0.23 | $-0.20 | $-0.25 | 2 |
| Jun 2027 | $-0.22 | $-0.20 | $-0.24 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · The Motley Fool · MarketBeat · RTTNews- BNK Invest · Sep 29, 12:09 PM EDTTuesday 9/29 Insider Buying Report: ANNX, PDIBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- The Motley Fool · Aug 19, 9:58 AM EDTAnnexon (ANNX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 9:03 AM EDTAnnexon Q2 Earnings Call HighlightsAnnexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarte
- RTTNews · Aug 12, 7:09 AM EDTAnnexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon(RTTNews) – Annexon Biosciences, Inc. (ANNX), a clinical-stage biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, has reported its second-quarter 2026 financial results and provided business updates, with investors focusing on regulatory
- RTTNews · Jul 15, 11:41 PM EDTTop Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data(RTTNews) – Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy, and Veradermics after reporting positiv
- NASDAQ.com · Jun 29, 7:59 PM EDTAfter Hours Most Active for Jun 29, 2026 : CAG, NVDA, GANX, INN, AAPL, ARI, ANNX, RKT, CSCO, CMG, ACN, HTZThe NASDAQ 100 After Hours Indicator is down -47.33 to 30,229.02. The total After hours volume is currently 289,974,742 shares traded.The following are the most active stocks for the after hours session: ConAgra Brands, Inc. (CAG) is -0.02 at $13.96, with 76,796,445 shares trade
- BNK Invest · Jun 16, 5:32 PM EDTAnnexon Enters Oversold Territory (ANNX)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- MarketBeat · Jun 9, 9:06 AM EDTAnnexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings AheadAnnexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-
- MarketBeat · Jun 4, 3:07 AM EDTAnnexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug ReadoutAnnexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin d
- BNK Invest · Jun 1, 11:59 AM EDTMonday 6/1 Insider Buying Report: ANNX, CDNLBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- MarketBeat · May 14, 4:05 AM EDTAnnexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA ConferenceAnnexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrom
- Fintel · May 12, 4:31 PM EDTGoldman Sachs Initiates Coverage of Annexon (ANNX) with Neutral RecommendationFintel reports that on May 12, 2026, Goldman Sachs initiated coverage of Annexon (NasdaqGS:ANNX) with a Neutral recommendation. Analyst Price Forecast Suggests 164.24% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Annexon, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.